Micro-invasive glaucoma surgery (MIGS) is gaining interest in very recent years, due to a better safety profile and good tensional results, often associated to cataract surgery. Glaukos iStent ® is the only FDA-approved device for micro-invasive glaucoma surgery. It connects the anterior chamber to Schlemm´s canal by bypassing the trabecular meshwork, increasing the outflow facility. The Glaukos iStent is In combined surgery, when phacoemulsification has been completed and an intraocular lens has been inserted, the anterior chamber should be refilled with a cohesive viscoelastic. The surgical microscope and the patient´s head then are repositioned and the angle is visualised with a gonio lens placed on the cornea. Finally, the inserter is introduced into the anterior chamber and the stent is placed into Schlemm´s canal through the trabecular meshwork. The stent is implanted through a temporal approach in a nasal position. If two implants are used, one is placed inferonasally and the other superonasally. The stent should be parallel to the iris root with the rails located on the back wall of Schlemm´s canal (see Figure 2 ).
chamber angle have been proposed to reduce post-operative scarring.
The purpose of these devices is to reduce intraocular pressure (IOP) by draining the aqueous humor through the collector channels.
The Glaukos iStent ® (Glaukos Corporation, Laguna Hills, California) is a 0.5 x 0.25 x 1 mm L-shaped, heparin-coated stent made of titanium (see Figure 1 ). The stent was designed to connect the anterior chamber to Schlemm´s canal by bypassing the trabecular meshwork, increasing the outflow facility and reducing the IOP. 6, 7, 8 Glaukos iStent ® has received FDA approval for the treatment of glaucoma in June 2012, being the only FDA-approved device for the treatment of mild to moderate open-angle glaucoma.
Spiegel et al. described the surgical technique. 9 The stent is ideal for implantation combined to phacoemulsification and the surgery can be performed under topical anaesthesia. The angle is easier to visualise and the surgery is easier to perform in pseudophakic eyes. To achieve a successful surgical outcome, the most important step is to have clear visualisation of the angle by tilting the operating microscope 30 degrees and turning the patient' head at least 45 degrees away from the surgeon.
In combined surgery, when phacoemulsification has been completed and an intraocular lens has been inserted, the anterior chamber should be refilled with a cohesive viscoelastic. The surgical microscope and the patient´s head then are repositioned and the angle is visualised with a gonio lens placed on the cornea. Finally, the inserter is introduced into the anterior chamber and the stent is placed into Schlemm´s canal through the trabecular meshwork. The stent is implanted through a temporal approach in a nasal position. If two implants are used, one is placed inferonasally and the other superonasally. The stent should be parallel to the iris root with the rails located on the back wall of Schlemm´s canal (see Figure 2 ). Table 1 ).
Spiegel et al. 9 ,11 studied stent implantation with concurrent cataract surgery in glaucoma patients at six and 12 months of follow-up, with significant IOP and antiglaucomatous drug use reduction in both studies.
Fernandez-Barrientos et al. 12 established a significant increase in trabecular outflow in cataract extraction with concomitant iStent implantation versus cataract surgery alone (275 and 46 % respectively, p=0.02). Craven et al. 15 have just published 2-year data from the same study.
At 24 months, the proportion of patients with IOP≤21 mmHg without ocular hypotensive medications was significantly higher in the stent group than in the control group (p=0.036). Overall, the mean IOP was stable between 12 months and 24 months (17.0 ± 2.8 mmHg and 17.1 ± 2.9 mmHg, respectively) in the stent group but increased (17.0 ± 3.1 mmHg to 17.8 ± 3.3 mmHg, respectively) in the control group. Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
Our group recently published the study with the longer follow-up, In almost all the studies just one iStent is implanted. Using a theoretical in vitro perfusion model, some authors predicted that more than just one iStent may increase facility of outflow and reduce IOP versus a single implant. Fernandez-Barrientos et al. 12 study versus other studies with just one iStent is consistent with that hypothesis. One very recently published article studied the efficacy of multiple iStent combined with cataract surgery in POAG and cataract. 17 The study involved 53 eyes, 28 had implantation of two stents and 25 had implantation of three stents. 
